Quantcast

Translate Bio prices upsized IPO at $13 midpoint


Shutterstock photo

Translate Bio, an early-stage biotech developing mRNA therapies for genetic diseases, raised $122 million by offering 9.4 million shares at $13, within the range of $12 to $14. The company had orginally planned to sell 7.7 million shares. Translate Bio plans to list on the Nasdaq under the symbol TBIO. Citi, Leerink Partners and Evercore ISI acted as lead managers on the deal.

The article Translate Bio prices upsized IPO at $13 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs










Research Brokers before you trade

Want to trade FX?